Adam Daniel Lipworth, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pemphigoid, Bullous | 1 | 2019 | 112 | 0.560 |
Why?
|
| Leishmania mexicana | 1 | 2015 | 33 | 0.510 |
Why?
|
| Scleromyxedema | 1 | 2014 | 7 | 0.490 |
Why?
|
| Paraplegia | 1 | 2015 | 161 | 0.480 |
Why?
|
| Interdisciplinary Communication | 1 | 2020 | 931 | 0.480 |
Why?
|
| Granuloma Annulare | 1 | 2014 | 29 | 0.470 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2019 | 311 | 0.470 |
Why?
|
| Epidural Abscess | 1 | 2015 | 94 | 0.460 |
Why?
|
| Complex Regional Pain Syndromes | 1 | 2015 | 121 | 0.450 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 2015 | 136 | 0.440 |
Why?
|
| Hidradenitis Suppurativa | 1 | 2016 | 177 | 0.420 |
Why?
|
| Erythema | 2 | 2015 | 262 | 0.410 |
Why?
|
| Exanthema | 2 | 2012 | 503 | 0.350 |
Why?
|
| Inflammatory Breast Neoplasms | 1 | 2012 | 147 | 0.340 |
Why?
|
| Foot Dermatoses | 1 | 2009 | 47 | 0.330 |
Why?
|
| Hand Dermatoses | 1 | 2009 | 62 | 0.330 |
Why?
|
| beta-Lactamases | 3 | 2006 | 304 | 0.330 |
Why?
|
| Benzenesulfonates | 1 | 2009 | 166 | 0.320 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2011 | 392 | 0.320 |
Why?
|
| Paresthesia | 1 | 2009 | 161 | 0.310 |
Why?
|
| Brachytherapy | 1 | 2016 | 1223 | 0.310 |
Why?
|
| Klebsiella Infections | 3 | 2006 | 144 | 0.310 |
Why?
|
| Critical Care | 1 | 2020 | 2696 | 0.300 |
Why?
|
| Skin | 3 | 2016 | 4473 | 0.280 |
Why?
|
| Drug Eruptions | 1 | 2009 | 335 | 0.270 |
Why?
|
| Ceftazidime | 1 | 2006 | 57 | 0.260 |
Why?
|
| Escherichia coli Infections | 3 | 2006 | 518 | 0.250 |
Why?
|
| Palliative Care | 1 | 2020 | 3599 | 0.250 |
Why?
|
| Ceftriaxone | 1 | 2006 | 175 | 0.240 |
Why?
|
| Enterobacteriaceae | 1 | 2006 | 161 | 0.240 |
Why?
|
| Triage | 1 | 2011 | 985 | 0.230 |
Why?
|
| Pyrroles | 1 | 2009 | 1124 | 0.220 |
Why?
|
| Indoles | 1 | 2009 | 1830 | 0.190 |
Why?
|
| Dipeptidyl-Peptidases and Tripeptidyl-Peptidases | 1 | 2019 | 88 | 0.160 |
Why?
|
| Anti-Bacterial Agents | 5 | 2016 | 7407 | 0.150 |
Why?
|
| Pyridines | 1 | 2009 | 2872 | 0.150 |
Why?
|
| Finland | 1 | 2019 | 607 | 0.140 |
Why?
|
| Amputation Stumps | 1 | 2015 | 38 | 0.130 |
Why?
|
| Blister | 1 | 2015 | 86 | 0.120 |
Why?
|
| Ovarian Neoplasms | 1 | 2012 | 4872 | 0.120 |
Why?
|
| Remission, Spontaneous | 1 | 2015 | 384 | 0.120 |
Why?
|
| Cellulitis | 1 | 2016 | 208 | 0.120 |
Why?
|
| Thigh | 1 | 2015 | 239 | 0.120 |
Why?
|
| Health Services Accessibility | 1 | 2011 | 5425 | 0.110 |
Why?
|
| Mexico | 1 | 2015 | 757 | 0.100 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 1 | 2014 | 179 | 0.100 |
Why?
|
| Melanoma | 1 | 2011 | 5694 | 0.100 |
Why?
|
| Biopsy | 2 | 2016 | 6781 | 0.100 |
Why?
|
| Lasers, Dye | 1 | 2011 | 28 | 0.100 |
Why?
|
| Skin Neoplasms | 1 | 2011 | 5809 | 0.090 |
Why?
|
| Paired Box Transcription Factors | 1 | 2012 | 206 | 0.090 |
Why?
|
| Skin Diseases, Vascular | 1 | 2011 | 41 | 0.090 |
Why?
|
| Cutis Laxa | 1 | 2011 | 29 | 0.090 |
Why?
|
| Histocytochemistry | 1 | 2012 | 697 | 0.090 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2014 | 668 | 0.090 |
Why?
|
| Travel | 1 | 2015 | 796 | 0.080 |
Why?
|
| Hospitals, Urban | 1 | 2011 | 500 | 0.080 |
Why?
|
| Citalopram | 1 | 2011 | 402 | 0.070 |
Why?
|
| Niacinamide | 1 | 2009 | 413 | 0.070 |
Why?
|
| Syndrome | 2 | 2011 | 3271 | 0.070 |
Why?
|
| Microscopy | 1 | 2012 | 904 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2009 | 13632 | 0.070 |
Why?
|
| Hospitals, General | 1 | 2011 | 799 | 0.070 |
Why?
|
| Phenylurea Compounds | 1 | 2009 | 529 | 0.070 |
Why?
|
| Eosinophilia | 1 | 2011 | 557 | 0.070 |
Why?
|
| Klebsiella oxytoca | 1 | 2005 | 7 | 0.060 |
Why?
|
| Immunologic Factors | 1 | 2014 | 1589 | 0.060 |
Why?
|
| Klebsiella | 1 | 2005 | 49 | 0.060 |
Why?
|
| Humans | 17 | 2023 | 761208 | 0.060 |
Why?
|
| Population Groups | 1 | 2006 | 207 | 0.060 |
Why?
|
| Physicians | 1 | 2023 | 4584 | 0.060 |
Why?
|
| Breast Neoplasms | 1 | 2012 | 20982 | 0.060 |
Why?
|
| Middle Aged | 9 | 2016 | 220853 | 0.060 |
Why?
|
| Dermatitis, Atopic | 1 | 2011 | 731 | 0.050 |
Why?
|
| Fever | 1 | 2011 | 1618 | 0.050 |
Why?
|
| Klebsiella pneumoniae | 1 | 2005 | 249 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2019 | 22174 | 0.050 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2005 | 585 | 0.040 |
Why?
|
| Pain | 1 | 2015 | 5072 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2014 | 12976 | 0.040 |
Why?
|
| Male | 8 | 2016 | 360693 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 15841 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2012 | 11067 | 0.040 |
Why?
|
| Boston | 1 | 2011 | 9327 | 0.040 |
Why?
|
| Treatment Failure | 2 | 2016 | 2643 | 0.030 |
Why?
|
| Aged, 80 and over | 3 | 2012 | 58952 | 0.030 |
Why?
|
| Escherichia coli | 1 | 2005 | 4201 | 0.030 |
Why?
|
| Female | 6 | 2015 | 392544 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2016 | 64681 | 0.020 |
Why?
|
| Adult | 5 | 2015 | 221119 | 0.020 |
Why?
|
| Histamine Antagonists | 1 | 2011 | 93 | 0.020 |
Why?
|
| Oxazolidinones | 1 | 2011 | 98 | 0.020 |
Why?
|
| Prednisolone | 1 | 2011 | 324 | 0.020 |
Why?
|
| Acetamides | 1 | 2011 | 257 | 0.020 |
Why?
|
| Prognosis | 1 | 2009 | 29687 | 0.020 |
Why?
|
| Communication | 1 | 2023 | 3872 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2023 | 3808 | 0.020 |
Why?
|
| Risk Factors | 2 | 2009 | 74239 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2011 | 80674 | 0.010 |
Why?
|
| Anti-Infective Agents | 1 | 2011 | 983 | 0.010 |
Why?
|
| Pandemics | 1 | 2023 | 8663 | 0.010 |
Why?
|
| Drug Hypersensitivity | 1 | 2011 | 918 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2011 | 6304 | 0.010 |
Why?
|
| Adolescent | 2 | 2006 | 88298 | 0.010 |
Why?
|
| Aged | 3 | 2006 | 169288 | 0.010 |
Why?
|
| Phylogeny | 1 | 2005 | 2809 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 4851 | 0.010 |
Why?
|
| United States | 1 | 2023 | 72339 | 0.010 |
Why?
|
| Time Factors | 1 | 2005 | 39957 | 0.000 |
Why?
|
| Cohort Studies | 1 | 2005 | 41496 | 0.000 |
Why?
|